Puza P Sharma
Overview
Explore the profile of Puza P Sharma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
962
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dalal R, Sharma P, Bains K, Pruce J, Allegretti J
Inflamm Bowel Dis
. 2023 Oct;
30(10):1707-1713.
PMID: 37843044
Background: Tofacitinib is an oral JAK inhibitor for the treatment of ulcerative colitis (UC). We assessed outcomes through 78 weeks of tofacitinib therapy for UC in a real-world setting. Methods:...
2.
Chiorean M, Ha C, Hur P, Sharma P, Gruben D, Khan N
Dig Dis Sci
. 2023 Aug;
68(10):3985-3993.
PMID: 37639057
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aims: To evaluate real-world data in US patients with UC receiving tofacitinib. Methods:...
3.
Dalal R, Sharma P, Bains K, Pruce J, Allegretti J
Inflamm Bowel Dis
. 2023 Aug;
30(8):1419-1422.
PMID: 37619234
No abstract available.
4.
Dalal R, Sharma P, Bains K, Pruce J, Allegretti J
Inflamm Bowel Dis
. 2023 May;
30(3):395-401.
PMID: 37209416
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited. We compared 52-week outcomes...
5.
Chiorean M, Allegretti J, Sharma P, Chastek B, Salese L, Bell E, et al.
BMC Gastroenterol
. 2022 Jul;
22(1):356.
PMID: 35883049
No abstract available.
6.
Long M, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, et al.
Inflamm Bowel Dis
. 2022 Jun;
29(4):570-578.
PMID: 35700276
Background: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib...
7.
Chiorean M, Allegretti J, Sharma P, Chastek B, Salese L, Bell E, et al.
BMC Gastroenterol
. 2022 Apr;
22(1):177.
PMID: 35397501
Background: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib...
8.
Delea T, Kartashov A, Sharma P
J Pharm Technol
. 2021 Dec;
30(1):21-30.
PMID: 34860884
Lapatinib is an oral small molecule dual tyrosine kinase inhibitor that has been shown to improve time to progression versus capecitabine in women with HER2+ metastatic breast cancer (MBC) previously...
9.
Farraye F, Qazi T, Kotze P, Moore G, Mundayat R, Lawendy N, et al.
Aliment Pharmacol Ther
. 2021 Jun;
54(4):429-440.
PMID: 34165201
Background: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. Aims: To...
10.
Sardesai A, Dignass A, Quon P, Milev S, Cappelleri J, Kisser A, et al.
J Med Econ
. 2021 Jan;
24(1):279-290.
PMID: 33502905
Objectives: Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor for the treatment of ulcerative colitis (UC). This study assessed the cost-effectiveness of tofacitinib versus other available treatments for...